Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07679841 Nivolumab Squamous cell carcinoma of vulva Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07679841 clinical trial report covering Nivolumab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07679542 Artenimol Metabolic Dysfunction Associated Steatohepatitis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07679542 clinical trial report covering Artenimol, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07678593 Cetuximab Pancreatic Ductal Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07678593 clinical trial report covering Cetuximab, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07680595 Folic Acid Carotid Artery Diseases Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07680595 clinical trial report covering Folic Acid, Phase 1/2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07646860 Sotatercept Pulmonary arterial hypertension associated with connective tissue disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07646860 clinical trial report covering Sotatercept, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07647068 Fludarabine Phosphate Metastatic Gastrointestinal Stromal Tumor Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07647068 clinical trial report covering Fludarabine Phosphate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07646626 SSGJ-612 Locally Advanced Malignant Solid Neoplasm Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07646626 clinical trial report covering SSGJ-612, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07647614 ENERGI-F705 Parkinson Disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07647614 clinical trial report covering ENERGI-F705, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07647003 Sildenafil/Metformin/Leucine Hypertension Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07647003 clinical trial report covering Sildenafil/Metformin/Leucine, Phase 2, endpoints, sponsor, geography, readout timing and development white space
Latest Hotspot
8 min read
NCT07651475 Chidamide Refractory acute myeloid leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
NCT07651475 clinical trial report covering Chidamide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2071260044 Elacestrant hydrochloride ER-positive/HER2-negative Breast Cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
JPRN-jRCT2071260044 clinical trial report covering Elacestrant hydrochloride, Phase 2, endpoints, sponsor, geography, readout timing and development white
Latest Hotspot
8 min read
ChiCTR2600126789 Bevacizumab Recurrent Glioma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
4 August 2026
ChiCTR2600126789 clinical trial report covering Bevacizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.